Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at upcoming investor conferences in November 2020.

Moderna to Present at Upcoming Investor Conferences in November 2020

Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly.

Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances

Moderna Inc (NASDAQ: MRNA) reported mixed quarterly results Thursday and suggested an interim efficacy readout from the Phase 3 study is likely in November. The Moderna Bull Case: Moderna's vaccine timeline is intact, according to Needham analyst Alan Carr, who rates the shares a Buy with a $94 price target.

Moderna Bull, Bear On Q3 Report, Coronavirus Vaccine Timeline

Moderna is looking to get its vaccine emergency use approval. Moderna stock is worth at least one-third more from its Covid-19 vaccine.

Moderna Stock Will Jump in Value On Completing Covid-19 Vaccine Tests

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna named top employer by Science for sixth consecutive year.

Moderna Named Top Employer by Science for Sixth Consecutive Year

Biotech firm Moderna expects to have about 20 million doses of its experimental coronavirus vaccine ready to ship in the US by the end of the year. The Massachusetts-based drug developer will be prepared to distribute the vaccine, dubbed mRNA-1273, around the country if its late-stage clinical study proves that it works and the feds.

Moderna will have 20M COVID-19 vaccines ready by year's end

They all hinge on the biotech's COVID-19 vaccine candidate.

3 Reasons to Buy Moderna and 1 Reason to Sell

Moderna, Inc. (MRNA) CEO Stéphane Bancel on Q3 2020 Results - Earnings Call Transcript

AstraZeneca

Gilead Sciences

Johnson & Johnson

Pfizer

Update on the COVID Vaccine Race

BioNTech SE

Moderna and BioNtech surged in Thursday trades as investor focus on a successful COVID-19 vaccine remained heightened amid a surge in daily virus cases. Moderna traded higher by as much as 13%, while BioNtech jumped as much as 11%.

Moderna, BioNtech surge as COVID-19 vaccine development progresses amid virus spike (MRNA)

PFE/BNTX and MRNA remain the front-runners in the race to develop a COVID-19 vaccine. PFE has seen some delays but at least, we haven't passed an interim analysis without success.

Judgement Day Approaches For COVID-19 Vaccine Names

Those early results could show that mRNA-1273 is effective enough against COVID-19 -- but if not, it will have several shots to hit its goal.

Moderna Expects First Look at Coronavirus Vaccine Candidate Data in November

The biotech has plenty of cash and could be on the verge of its biggest success ever.

Why Investors Loved Moderna's Q3 Results

Prescription drugmaker Moderna has received $1.1 billion in customer deposits for its COVID-19 vaccine, expected to be available next year.

Moderna rakes in $1.1B on coronavirus vaccine orders

When Moderna Inc. (NASDAQ: MRNA) reported its most recent quarterly results before the markets opened on Thursday, the earnings (or loss in this case) were not the most important feature of the report.

Moderna's Financials Aren't Even the Best Part of Its Report

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) reported forecast-beating third-quarter revenues and a vaccine supply contract, sending shares higher. Moderna's Q3 Results: Cambridge, Massachusetts-based Moderna reported third-quarter revenues of $157.91 million, notably higher than the year-ago revenues of $17.05 million.

Moderna Q3 Revenues Beat Estimates, Inks Coronavirus Vaccine Supply Deal With Japan

Moderna (MRNA) delivered earnings and revenue surprises of -37.21% and 103.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates

Shares of Moderna Inc. were up 2.9% in premarket trading on Thursday after the company again reminded investors that the Phase 3 clinical trial for its COVID-19 vaccine candidate is fully enrolled as part of its third-quarter earnings announcement. It also said it is "actively preparing for the launch" of its COVID-19 vaccine.

Moderna's stock is up as it says it is 'actively preparing' for launch of COVID-19 vaccine

Moderna's Covid-19 vaccine development appears to be at its home stretch. Last week, the company said that it completed the enrollment process of 30,000 participants in its final-stage study, with initial data on the efficacy of the vaccine expected by late November.

What To Expect As Moderna's Vaccine Development Hits The Home Stretch

Moderna posted third-quarter results early Thursday that showed revenue jumping more than 800% but R&D costs tripling as the company strives to develop its Covid-19 vaccine; MRNA stock rose. The post Moderna Third-Quarter Earnings Show Soaring Revenue, R&D Costs appeared first on Investor's Business Daily.

Moderna Third-Quarter Earnings Show Soaring Revenue, R&D Costs

Moderna is prepping for the global launch of its potential coronavirus vaccine, already taking in $1.1 billion in deposits from governments awaiting the potentially lifesaving drug, the biotech firm said Thursday in its third-quarter earnings report.

Moderna says it's preparing global launch of Covid vaccine as it takes in $1.1 billion in deposits

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna reports third quarter 2020 financial results and provides business updates.

Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates

Takeda Pharmaceutical

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of mRNA vaccine against COVID-19 (mRNA-1273) to Japan.

Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan

Inovio Pharmaceuticals

Novavax

The overall stock market sell-off is pulling all three biotech stocks down.

Why Coronavirus Vaccine Stocks Moderna, Novavax, and Inovio Are Sinking Today

Moderna Inc (NASDAQ: MRNA), which is among the frontrunners in the race to develop a coronavirus vaccine, is set to release its third-quarter results Thursday before the market open. Q3 Expectations For Moderna: Analysts, on average, expect the company to report a loss per share of 43 cents on revenue of $77.51 million.

News for Moderna Stock (MRNA)